Humacyte, Inc.

Humacyte, Inc. — trading under the legacy SPAC ticker AHAC — filed an 8-K current report with the SEC on May 8, 2026 (accession no. 0001104659-26-057974), continuing its public-company disclosure obligations following its business combination with Alpha Healthcare Acquisition Corp. III, sponsored by Alpha Healthcare Holdings III LLC. The blank-check vehicle IPO'd in 2021 and was focused exclusively on the healthcare and life sciences sector before merging with Humacyte, a Durham, North Carolina–based biotechnology company developing bioengineered human acellular vessels for vascular reconstruction and repair. The combined company has remained active in SEC filings since the deal closed. Sign up for SpacDesk to access the full filing history, deal terms, and ongoing corporate events for AHAC and hundreds of other SPAC transactions.